Staff

CureVac Doses First Participant in Phase 1 Study with Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration with GSK

- Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains- Influenza candidate developed in collaboration...

error: Content is protected !!